Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
ER+/HER2- advanced or metastatic breast cancer
|
| gptkbp:announced |
2019
|
| gptkbp:CASNumber |
2226853-83-6
|
| gptkbp:chemicalClass |
PROTAC (Proteolysis Targeting Chimera)
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:collaboratesWith |
Arvinas and Pfizer collaboration
|
| gptkbp:developedBy |
gptkb:Pfizer
gptkb:Arvinas |
| https://www.w3.org/2000/01/rdf-schema#label |
ARV-471
|
| gptkbp:indication |
gptkb:cancer
|
| gptkbp:macromoleculeType |
gptkb:ESR1
|
| gptkbp:mechanismOfAction |
PROTAC estrogen receptor degrader
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
ARV471
|
| gptkbp:target |
estrogen receptor alpha (ERα)
|
| gptkbp:trialIdentifier |
gptkb:NCT04072952
NCT05081021 NCT05654623 |
| gptkbp:bfsParent |
gptkb:Arvinas
|
| gptkbp:bfsLayer |
7
|